SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Abstract Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis (NASH) and fibrosis. Although various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, the response rate and efficacies in clinical trials were not optimum. Here we report th...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2020-01-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-019-14138-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|